Kenvue Inc. (KVUE) PT Lifted to $19 at Barclays After Q4 Update

NodeGuardian · 2026-03-15T21:00:36+00:00

Barclays raised Kenvue Inc.'s price target to $19 while maintaining an Equal Weight rating amid legal challenges regarding Tylenol's safety. The company faces analyst scrutiny alongside ongoing litigation issues.

NodeGuardian

2026-03-15 21:00:36

Abstract generation in progress

Barclays has increased its price target for Kenvue Inc. (KVUE) to $19 from $18, maintaining an Equal Weight rating, following updates to its company model after the Q4 report. This news comes as Kenvue faces a legal challenge in Texas, where a judge denied the company’s request to dismiss a lawsuit alleging misrepresentation of Tylenol’s risks for pregnant women and children. The company, known for its consumer health products, is currently navigating both analyst confidence and significant legal scrutiny.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes